Hikma Pharmaceuticals Share Discussion Threads

[coppertrader] 17/7/2015 13:15

London, 15 July 2015 – Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces it has it has received approval from the U.S. Food and Drug Administration ("FDA") for its supplemental Abbreviated New Drug Application ("sANDA") for thiotepa for injection USP, 15mg/vial.Thiotepa is indicated for the palliation of a wide variety of neoplastic diseases, with the most consistent results seen in tumors related to adenocarcinoma of the breast and ovary. It will be the second product previously marketed by Bedford Laboratories to be launched by Hikma in the United States. Thiotepa is currently on the FDA's Drug Shortages list and Hikma has the only approved active US ANDA.Said Darwazah, Chairman and CEO of Hikma said, "We are making good progress with the transfer of the Bedford products to our manufacturing facilities, leveraging our strong R&D, regulatory and manufacturing capabilities. Thiotepa is used in the treatment of a variety of cancers. It has been on shortage in the US for several years and we are very pleased to be able to provide a resolution to this critical situation."More:

[e factor] 28/6/2015 18:26

Should we be bracing ourselves for 1800p?

[e factor] 21/6/2015 22:29

I would be keen to hear of any stocks, peeps think are about to begin a strong run up over years, like Hikma has done.

Any ideas?

[e factor] 20/6/2015 19:22

Remember, we're playing in a defensive sector here.

[salpara111] 18/6/2015 12:43

have been watching for a while but it was clearly overbought, partly due to it being run up on entry to the FTSE 100.
The problem now is that the market cap has fallen back far enough that it would be relegated if there was a reshuffle tomorrow.
I am keeping them on my monitor but am mostly in cash until I see what the clowns in Greece do.
If they really do decide to push the self destruct button I would imagine there will be a market drop around 3-5% but it will be relatively short lived and as such I see it as a buying opportunity.

[r ball] 16/6/2015 20:56

Revert to mean. It's just noise. Ignore

[coppertrader] 16/6/2015 11:58

Whats going on with this sp? Any reason for the constant decline?

[modform] 19/5/2015 12:52

Good solid company, I have been buying dips in the past few days..

[broadwood] 18/5/2015 14:09

Shares in Hikma Pharmaceuticals were under pressure on Monday, down 2% after the company said its founder and major shareholder, Samih Darwazah, passed away last Friday at the age of 85.
Hikma floated on the London Stock Exchange in 20105 and entered the FTSE 100 index in March 2015, replacing Tullow Oil.

Darwazah founded Hikma in 1978 in Amman, Jordan, with the aim of bringing high-quality and affordable medicines to the world. With the help of his children, who joined the business in its early days, Hikma grew from a small factory in Jordan into the largest regional supplier of pharmaceuticals in the Middle East and North Africa.

The company also expanded outside the MENA region, establishing successful operations in Europe and the United States. Today, it operates in around 50 countries, selling a broad range of branded generics, generic injectables, non-injectable generics and in-licensed patented products.

[broadwood] 14/5/2015 10:26

Hikma Pharmaceuticals said it had enjoyed a good start to the year and said revenues at its Injectables division would remain at a similar level to last year's but with a slight decline in operating profit margins.
Ahead of its annual shareholder meeting on Thursday, the FTSE 100 group reiterated its overall full year guidance of 6% revenue growth in constant currency, with currency fluctuations would flatten turnover growth to just 2% at the reported levels.

Currently the consensus forecast for full year adjusted profit before tax stands at around $374m.

Hikma said first half revenues were likely to be flat against the extremely strong performance last year, with the second half providing the expected bulk of revenue growth for the full year.

[broadwood] 12/5/2015 15:38

Hikma Pharmaceuticals on Tuesday launched a caffeine citrate injection to treat apnea resulting from prematurity in infants of between 28 and 33 weeks of gestational age.
The company noted that sales of caffeine citrate injections in the US last year were of $7.6m.

Chairman and chief executive Said Darwazah said: "This is our first launch from the Bedford portfolio acquired last year.

"We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities

[coppertrader] 22/4/2015 13:15

The mylan news is worth a read. They appear to be buying out other generics drug companies to grow so that they can not be brought out by teva. Interesting times

[r ball] 22/4/2015 06:36

read across from Mylan?

[johnthespacer] 17/4/2015 13:56

Proposed final dividend of 15.0 cents per share (22.0 cents per share for the full year), plus a special dividend of 6.0 cents per share (10.0 cents per share for the full year), making a total combined dividend for the year of 32.0 cents per share

[johnthespacer] 17/4/2015 13:37

Ex dividend on 16/04/15 so this is part of the drop reason... i must look to see how much we are getting this time

[megordon] 16/4/2015 16:43

Went long earlier today, hoping this is a double bottom and ready for a bit of a bounce now.

GLA.

[stats11] 02/4/2015 19:53

Prime Takeover target.

[r ball] 01/4/2015 21:02

why the money?

[rosieoutlook] 23/3/2015 12:35

From FT March 13th: Hikma Pharmaceuticals was down 5.3 per cent to £22.31 after Citi analysts speculated about a possible bid for Roxane Laboratories, the $2.4bn-valued US generic drugmaker owned by Boehringer Ingelheim.

Presumably the reason for requiring the bond.

[blackswan23] 23/3/2015 09:12

Broadwood- thanks for information regarding Hikma releasing bonds in a re financing initiative. I've been looking around for some time for some information as to why my Hikma shares are losing value. I'm holding on for their promotion to the FTSE 100. Can only wonder what the big need for refinancing is.

[r ball] 17/3/2015 19:57

Ps: sorry I have thrown it out. Don't have further details.

[coppertrader] 17/3/2015 18:26

Whats the cash needed for? Any ideas?